{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T16:04:20Z","timestamp":1780329860926,"version":"3.54.1"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.msard.2026.107195","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T07:44:36Z","timestamp":1775634276000},"page":"107195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world transition from uncontrolled disease to stability: Three-year Pre-post natalizumab comparison in relapsing multiple sclerosis"],"prefix":"10.1016","volume":"110","author":[{"given":"Serkan","family":"Ozakbas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0769-4853","authenticated-orcid":false,"given":"Orkhan","family":"Mammadov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said","family":"Alizada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulvi","family":"Samadzade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Caliskan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasemin","family":"Simsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.msard.2026.107195_bib0009","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-02665-6","article-title":"Experiences in treatment of multiple sclerosis with natalizumab from a real-life cohort over 15 years","volume":"11","author":"Auer","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.msard.2026.107195_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.699844","article-title":"Long-term efficacy outcomes of Natalizumab vs. Fingolimod in patients with highly active relapsing-remitting multiple sclerosis: real-world data from a Multiple sclerosis reference center","volume":"12","author":"Boziki","year":"2021","journal-title":"Front. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2026.107195_bib0008","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1136\/jnnp-2013-306936","article-title":"Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results","volume":"85","author":"Butzkueven","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"issue":"4","key":"10.1016\/j.msard.2026.107195_bib0004","article-title":"Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: a propensity-matched study","volume":"21","author":"Chisari","year":"2024","journal-title":"J. America. Soc. Experiment. Neurotherapeuti."},{"key":"10.1016\/j.msard.2026.107195_bib0016","doi-asserted-by":"crossref","unstructured":"Clerico, M., et al., Natalizumab in Multiple Sclerosis: Long-Term Management. Inter. j. mole. scie. 18,5 940. 2017, doi:10.3390\/ijms18050940.","DOI":"10.3390\/ijms18050940"},{"issue":"3","key":"10.1016\/j.msard.2026.107195_bib0006","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00415-009-0093-1","article-title":"The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL","volume":"256","author":"Hutchinson","year":"2009","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2026.107195_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.549842","article-title":"Natalizumab in multiple sclerosis treatment: from biological effects to Immune monitoring","volume":"11","author":"Khoy","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2026.107195_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.714941","article-title":"Real-world effectiveness of Natalizumab in Korean patients with multiple sclerosis","volume":"12","author":"Kim","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2026.107195_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103995","article-title":"Use of natalizumab in persons with multiple sclerosis: 2022 update","volume":"65","author":"Morrow","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2026.107195_bib0012","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4274\/jmsr.galenos.2024.2024-4-2","article-title":"Natalizumab in multiple sclerosis: a single centre real-world study","volume":"4","author":"Onder","year":"2024","journal-title":"J. Multiple Sclerosis Res."},{"issue":"1","key":"10.1016\/j.msard.2026.107195_bib0013","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12883-019-1337-z","article-title":"Outcomes of natalizumab treatment within 3\u2009years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE","volume":"19","author":"Perumal","year":"2019","journal-title":"BMC. Neurol."},{"issue":"9","key":"10.1016\/j.msard.2026.107195_bib0005","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2026.107195_bib0015","first-page":"1","article-title":"Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis","volume":"12","author":"Prosperini","year":"2019","journal-title":"Thera. adva. neuro. diso."},{"issue":"15","key":"10.1016\/j.msard.2026.107195_bib0014","doi-asserted-by":"crossref","first-page":"e1452","DOI":"10.1212\/WNL.0000000000008243","article-title":"Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing","volume":"93","author":"Ryerson","year":"2019","journal-title":"Neurology."},{"issue":"1","key":"10.1016\/j.msard.2026.107195_bib0010","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1186\/s12883-023-03297-1","article-title":"Long-term effects of natalizumab on MRI activity and clinical outcomes in Japanese patients with relapsing-remitting multiple sclerosis","volume":"23","author":"Saida","year":"2023","journal-title":"BMC. Neurol."},{"issue":"9","key":"10.1016\/j.msard.2026.107195_bib0007","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/1756285617716002","article-title":"The role of natalizumab in the treatment of multiple sclerosis: benefits and risks","volume":"10","author":"Singer","year":"2017","journal-title":"Ther. Adv. Neurol. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826002312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826002312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T15:24:40Z","timestamp":1780327480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826002312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":16,"alternative-id":["S2211034826002312"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107195","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world transition from uncontrolled disease to stability: Three-year Pre-post natalizumab comparison in relapsing multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107195","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107195"}}